IPP Bureau
VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes
By IPP Bureau - February 23, 2026
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Morepen Labs lands record Rs. 825 crore global CDMO contract
By IPP Bureau - February 23, 2026
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Lupin receives European Commission approval for biosimilar Ranibizumab
By IPP Bureau - February 23, 2026
BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia
By IPP Bureau - February 23, 2026
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Merck restructures Human Health division for future growth
By IPP Bureau - February 23, 2026
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator
By IPP Bureau - February 22, 2026
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial
By IPP Bureau - February 22, 2026
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
Lonza scales bioconjugate innovation through enhanced synthesis offering
By IPP Bureau - February 21, 2026
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
FDA accepts Teva’s NDA for long-acting schizophrenia injection
By IPP Bureau - February 21, 2026
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill
By IPP Bureau - February 21, 2026
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients
By IPP Bureau - February 21, 2026
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
FDA accepts Roche’s new drug application for Giredestrant in advanced breast cancer
By IPP Bureau - February 21, 2026
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Novartis bags Phase III win for Remibrutinib in chronic inducible urticaria
By IPP Bureau - February 20, 2026
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
BIOEMTECH & NorthStar strike deal to boost access to critical Actinium-225 for preclinical research
By IPP Bureau - February 20, 2026
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
Johnson & Johnson bags FDA nod for monthly RYBREVANT FASPRO dosing in advanced lung cancer
By IPP Bureau - February 20, 2026
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
